The BioPharm Brief: Survodutide Data, Orca-Q RMAT, Ligand Deal

Apr 28, 09:26 PM
Headliner
Share
Subscribe

Survodutide delivers significant Phase III weight loss results, FDA grants RMAT status to Orca-Q, and Ligand expands its portfolio with a $739 million acquisition of XOMA.

Share
Subscribe
Next
The BioPharm Brief: Biosimilar Approval, Elrexfio Data, SOX2 Innovation
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief